Search

Your search keyword '"Mirjolet, Céline"' showing total 158 results
Start Over Author "Mirjolet, Céline"
158 results on '"Mirjolet, Céline"'

1. Targeted radionuclide therapy against GARP expressing T regulatory cells after tumour priming with external beam radiotherapy in a murine syngeneic model

Author

Bellaye, Pierre-Simon, Dias, Alexandre MM., Vrigneaud, Jean-Marc, Bouchard, Alexanne, Moreau, Mathieu, Petitot, Camille, Bernhard, Claire, Claron, Michael, Froidurot, Lisa, Morgand, Véronique, Guillemin, Mélanie, Monterrat, Marie, Mirjolet, Céline, Garrido, Carmen, Kohli, Evelyne, and Collin, Bertrand

Published
2024
Full Text
View/download PDF

3. A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

Author

Roussot, Nicolas, Fumet, Jean-David, Limagne, Emeric, Thibaudin, Marion, Hervieu, Alice, Hennequin, Audrey, Zanetta, Sylvie, Dalens, Lorraine, Fourrier, Théo, Galland, Loick, Jacob, Pierre, Bertaut, Aurélie, Rederstorff, Emilie, Chevalier, Cédric, Ghirardi, Sarah, Gilbert, Elodie, Khoukaz, Azzat, Martin, Etienne, Nicolet, Constance, Quivrin, Magali, Thibouw, David, Vulquin, Noémie, Truc, Gilles, Rouffiac, Magali, Ghiringhelli, Francois, and Mirjolet, Céline

Published
2023
Full Text
View/download PDF

7. Challenges in glioblastoma research: focus on the tumor microenvironment

Author

Bikfalvi, Andreas, da Costa, Cristine Alves, Avril, Tony, Barnier, Jean-Vianney, Bauchet, Luc, Brisson, Lucie, Cartron, Pierre Francois, Castel, Hélène, Chevet, Eric, Chneiweiss, Hervé, Clavreul, Anne, Constantin, Bruno, Coronas, Valérie, Daubon, Thomas, Dontenwill, Monique, Ducray, Francois, Entz-Werlé, Natacha, Figarella-Branger, Dominique, Fournier, Isabelle, Frenel, Jean-Sébastien, Gabut, Mathieu, Galli, Thierry, Gavard, Julie, Huberfeld, Gilles, Hugnot, Jean-Philippe, Idbaih, Ahmed, Junier, Marie-Pierre, Mathivet, Thomas, Menei, Philippe, Meyronet, David, Mirjolet, Céline, Morin, Fabrice, Mosser, Jean, Moyal, Elisabeth Cohen-Jonathan, Rousseau, Véronique, Salzet, Michel, Sanson, Marc, Seano, Giorgio, Tabouret, Emeline, Tchoghandjian, Aurélie, Turchi, Laurent, Vallette, Francois M., Vats, Somya, Verreault, Maité, and Virolle, Thierry

Published
2023
Full Text
View/download PDF

9. Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model

Author

Boustani, Jihane, primary, Lecoester, Benoit, additional, Baude, Jérémy, additional, Latour, Charlène, additional, Limagne, Emeric, additional, Ladjohoulou, Riad, additional, Morgand, Véronique, additional, Froidurot, Lisa, additional, Ghiringhelli, François, additional, Truc, Gilles, additional, Adotévi, Olivier, additional, and Mirjolet, Céline, additional

Published
2024
Full Text
View/download PDF

10. Supramolecular Heterodimer Peptides Assembly for Nanoparticles Functionalization

Author

Mathieu, Clélia, primary, Ghosh, Shayamita, additional, Draussin, Julien, additional, Gasser, Adeline, additional, Jacquot, Guillaume, additional, Banerjee, Mainak, additional, Gupta, Tanushree, additional, Schmutz, Marc, additional, Mirjolet, Céline, additional, Tillement, Olivier, additional, Lux, François, additional, Klymchenko, Andrey S., additional, Donzeau, Mariel, additional, Pivot, Xavier, additional, Harlepp, Sébastien, additional, and Detappe, Alexandre, additional

Published
2024
Full Text
View/download PDF

11. Subcutaneous Administration of a Zwitterionic Chitosan‐Based Hydrogel for Controlled Spatiotemporal Release of Monoclonal Antibodies (Adv. Mater. 13/2024)

Author

Gréa, Thomas, primary, Jacquot, Guillaume, additional, Durand, Arthur, additional, Mathieu, Clélia, additional, Gasser, Adeline, additional, Zhu, Chen, additional, Banerjee, Mainak, additional, Hucteau, Elyse, additional, Mallard, Joris, additional, Lopez Navarro, Pedro, additional, Popescu, Bogdan V., additional, Thomas, Eloise, additional, Kryza, David, additional, Sidi‐Boumedine, Jacqueline, additional, Ferrauto, Giuseppe, additional, Gianolio, Eliana, additional, Fleith, Guillaume, additional, Combet, Jérôme, additional, Brun, Susana, additional, Erb, Stéphane, additional, Cianferani, Sarah, additional, Charbonnière, Loïc J., additional, Fellmann, Lyne, additional, Mirjolet, Céline, additional, David, Laurent, additional, Tillement, Olivier, additional, Lux, François, additional, Harlepp, Sébastien, additional, Pivot, Xavier, additional, and Detappe, Alexandre, additional

Published
2024
Full Text
View/download PDF

14. HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells

Author

Causse, Sebastien Z., Marcion, Guillaume, Chanteloup, Gaëtan, Uyanik, Burhan, Boudesco, Christophe, Grigorash, Bogdan B., Douhard, Romain, Dias, Alexandre M. M., Dumetier, Baptiste, Dondaine, Lucile, Gozzi, Gustavo J., Moussay, Etienne, Paggetti, Jérôme, Mirjolet, Céline, de Thonel, Aurélie, Dubrez, Laurence, Demidov, Oleg N., Gobbo, Jessica, and Garrido, Carmen

Published
2019
Full Text
View/download PDF

30. Factors associated with dosimetric changes and value of adaptive radiotherapy in patients undergoing radiotherapy for head and neck cancer

Author

Bonnet, Flore, primary, Créhange, Gilles, additional, Berthaut, Aurélie, additional, Fouquier, Anais, additional, Truc, Gilles, additional, Chevalier, Cédric, additional, Roukoz, Camille, additional, Mirjolet, Céline, additional, Bidault, Fabienne, additional, Vulquin, Noémie, additional, and Thibouw, David, additional

Published
2023
Full Text
View/download PDF

32. Factors associated with dosimetric changes and value of adaptive radiotherapy in patients undergoing radiotherapy for head and neck cancer

Author

Bonnet, Flore, primary, Créhange, Gilles, additional, Berthaut, Aurélie, additional, Fouquier, Anais, additional, Truc, Gilles, additional, Chevalier, Cédric, additional, Roukoz, Camille, additional, Mirjolet, Céline, additional, Bidault, Fabienne, additional, Vulquin, Noémie, additional, and Thibouw, David, additional

Published
2022
Full Text
View/download PDF

36. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study

Author

Deneuve, Sophie, primary, Bastogne, Thierry, additional, Duclos, Mirlande, additional, Mirjolet, Céline, additional, Bois, Pascaline, additional, Bachmann, Patrick, additional, Nokovitch, Lara, additional, Roux, Pierre-Eric, additional, Girodet, Didier, additional, Poupart, Marc, additional, Zrounba, Philippe, additional, Claude, Line, additional, Ferella, Letizia, additional, Iacovelli, Nicola Alessandro, additional, Foray, Nicolas, additional, Rancati, Tiziana, additional, and Pereira, Sandrine, additional

Published
2022
Full Text
View/download PDF

37. sj-docx-1-tmj-10.1177_03008916221078061 – Supplemental material for Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study

Author

Deneuve, Sophie, Bastogne, Thierry, Duclos, Mirlande, Mirjolet, Céline, Bois, Pascaline, Bachmann, Patrick, Nokovitch, Lara, Roux, Pierre-Eric, Girodet, Didier, Poupart, Marc, Zrounba, Philippe, Claude, Line, Ferella, Letizia, Iacovelli, Nicola Alessandro, Foray, Nicolas, Rancati, Tiziana, and Pereira, Sandrine

Subjects
Medicine
Abstract

Supplemental material, sj-docx-1-tmj-10.1177_03008916221078061 for Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study by Sophie Deneuve, Thierry Bastogne, Mirlande Duclos, Céline Mirjolet, Pascaline Bois, Patrick Bachmann, Lara Nokovitch, Pierre-Eric Roux, Didier Girodet, Marc Poupart, Philippe Zrounba, Line Claude, Letizia Ferella, Nicola Alessandro Iacovelli, Nicolas Foray, Tiziana Rancati and Sandrine Pereira in Tumori Journal

Published
2022
Full Text
View/download PDF

38. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy

Author

Lauret Marie Joseph, Elodie, Kirilovsky, Amos, Lecoester, Benoît, El Sissy, Carine, Boullerot, Laura, Rangan, Laurie, Marguier, Amélie, Tochet, Florent, Dosset, Magalie, Boustani, Jihane, Ravel, Patrice, Boidot, Romain, Spehner, Laurie, Haicheur-Adjouri, Nacilla, Marliot, Florence, Pallandre, Jean-René, Bonnefoy, Francis, Scripcariu, Viorel, Van den Eynde, Marc, Cornillot, Emmanuel, Mirjolet, Céline, Pages, Franck, Adotevi, Olivier, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, and UCL - (SLuc) Unité d'oncologie médicale

Subjects
Cancer Research, Immunology, Mice, Tumor Microenvironment, Immunology and Allergy, Animals, Humans, Immune Checkpoint Inhibitors, radiotherapy, RC254-282, Pharmacology, combination, Immunity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Basic Tumor Immunology, adaptive immunity, Chemoradiotherapy, Th1 Cells, drug therapy, Disease Models, Animal, Oncology, Molecular Medicine, Female, Immunotherapy
Abstract

BACKGROUND: Multiple synergistic combination approaches with cancer drugs are developed to overcome primary resistance to immunotherapy; however, the mechanistic rationale to combine chemoradiotherapy (CRT) with immune checkpoint inhibitors remains elusive. METHODS: This study described the immunological landscape of tumor microenvironment (TME) exposed to CRT. Tumor samples from patients with rectal cancer (n=43) treated with neoadjuvant CRT or radiotherapy were analyzed by nanostring and immunohistochemistry. Studies in mice were performed using three syngeneic tumors (TC1, CT26 and MC38). Tumor-bearing mice were treated either with platinum-based CRT, radiotherapy or chemotherapy. Anti-CTLA-4 and/or anti-Programmed Cell Death Receptor-1 (PD-1) therapy was used in combination with CRT. The therapy-exposed TME was screened by RNA sequencing and flow cytometry and tumor-infiltrating T lymphocyte functionality was evaluated by interferon (IFN)-γ ELIspot and intracellular cytokine staining. RESULTS: Front-to-front comparison analysis revealed the synergistic effect of CRT to establish a highly inflamed and Th1-polarized immune signature in the TME of patients and mice. In both settings, CRT-exposed TMEs were highly enriched in newly-infiltrated tumor-specific CD8+ T cells as well as tissue resident memory CD103+CD8+ T cells. In mice, CD8 T cells were involved in the antitumor response mediated by CRT and were primed by CRT-activated CD103+ dendritic cells. In the three tumor models, we showed that concurrent combination of CRT with a dual CTLA-4 and PD-1 blockade was required to achieve an optimal antitumor effect and to establish a broad and long-lasting protective antitumor T cell immunity. CONCLUSIONS: Our results highlight the ability of CRT to stimulate strong antitumor T-cell-mediated immunity and tissue resident memory T activation in TME, to foster immune checkpoint inhibitors action. These findings have implications in clinic for the design clinical trials combining chemoradiation with immunotherapy.

Published
2021

40. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study

Author

Deneuve, Sophie, Bastogne, Thierry, Duclos, Mirlande, Mirjolet, Céline, Bois, Pascaline, Bachmann, Patrick, Nokovitch, Lara, Roux, Pierre-Eric, Girodet, Didier, Poupart, Marc, Zrounba, Philippe, Claude, Line, Ferella, Letizia, Iacovelli, Nicola Alessandro, Foray, Nicolas, Rancati, Tiziana, and Pereira, Sandrine

Abstract

Objective: Radiotherapy (RT) against head and neck squamous cell carcinomas (HNSCC) may lead to severe toxicity in 30-40% of patients. The normal tissue complication probability (NTCP) models, based on dosimetric data refined the normal tissue dose/volume tolerance guidelines. In parallel, the radiation-induced nucleoshuttling (RIANS) of the Ataxia-Telangiectasia Mutated protein (pATM) is a predictive approach of individual intrinsic radiosensitivity. Here, we combined NTCP with RADIODTECT©, a blood assay derived from the RIANS model, to predict RT toxicity in HNSCC patients.Methods: RADIODTECT© cutoff values (i.e. 57.8 ng/mL for grade⩾2 toxicity and 46 ng/mL for grade⩾3 toxicity) have been previously assessed. Validation was performed on a prospective cohort of 36 HNSCC patients treated with postoperative RT. Toxicity was graded with the Common Terminology Criteria for Adverse Events (CTCAE) scale and two criteria were considered: grade⩾2 oral mucositis (OM2), grade⩾3 mucositis (OM3) and grade⩾2 dysphagia (DY2), grade⩾3 dysphagia (DY3). pATM quantification was assessed in lymphocytes of HNSCC patients. The discrimination power of the pATM assay was evaluated through the Area Under the Receiver Operator Characteristics Curve (AUC-ROC). Two previously described NTCP models were considered, including the dose to the oral cavity and the mean dose to the parotid glands (OM2 and OM3) and the dose to the oral cavity, to the larynx and the volume of pharyngeal constrictor muscles (DY2 and DY3).Results: Combining NTCP models with RADIODTECT© blood test improved the AUC-ROC. Considering the prediction of mucositis, AUC-ROCNTCP+RADIODTECT©=0.80 was for OM2, and AUC-ROCNTCP+RADIODTECT©=0.78 for OM3. Considering the prediction of acute dysphagia, AUC-ROCNTCP+RADIODTECT©=0.71 for DY2 and for DY3.Conclusions: Combining NTCP models with a radiosensitivity biomarker might significantly improve the prediction of toxicities for HNSCC patients.

Published
2023
Full Text
View/download PDF

42. Additional file 3 of Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood

Author

Boustani, Jihane, Joseph, Elodie Lauret Marie, Martin, Etienne, Benhmida, Salim, Lecoester, Benoit, Tochet, Florent, Mirjolet, Céline, Chevalier, Cédric, Thibouw, David, Vulquin, Noémie, Servagi, Stéphanie, Sun, Xushan, and Adotévi, Olivier

Abstract

Additional file 3: Supplementary Table S1. List of monoclonal antibodies used for flow cytometry.

Published
2021
Full Text
View/download PDF

43. Additional file 2 of Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood

Author

Boustani, Jihane, Joseph, Elodie Lauret Marie, Martin, Etienne, Benhmida, Salim, Lecoester, Benoit, Tochet, Florent, Mirjolet, Céline, Chevalier, Cédric, Thibouw, David, Vulquin, Noémie, Servagi, Stéphanie, Sun, Xushan, and Adotévi, Olivier

Abstract

Additional file 2: Supplementary Figure S2. Kaplan-Meier overall survival (OS) curves in patients according to TERT specific T-cell responses and immunosuppressive cells levels before and after CRT. OS according toTERT-specific responses levels (A), MDSC levels (B), andTreg levels (C).

Published
2021
Full Text
View/download PDF

44. Additional file 1 of Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood

Author

Boustani, Jihane, Joseph, Elodie Lauret Marie, Martin, Etienne, Benhmida, Salim, Lecoester, Benoit, Tochet, Florent, Mirjolet, Céline, Chevalier, Cédric, Thibouw, David, Vulquin, Noémie, Servagi, Stéphanie, Sun, Xushan, and Adotévi, Olivier

Subjects
hemic and immune systems, chemical and pharmacologic phenomena
Abstract

Additional file 1: Supplementary Figure S1. Gating strategy for flow cytometry analyses. The figure shows the gating strategy to Treg (A) and MDSC (B) populations. Frequencies of Treg cells were observed in CD4 T-cell population. Expression of CD127, FoxP3, and CTLA4 were analyzed on Treg (A). MDSC populations were analyzed after exclusion of lineage (CD3, CD56, CD19)(B).

Published
2021
Full Text
View/download PDF

45. Proof of Concept of a Binary Blood Assay for Predicting Radiosensitivity

Author

Deneuve, Sophie, primary, Mirjolet, Céline, additional, Bastogne, Thierry, additional, Duclos, Mirlande, additional, Retif, Paul, additional, Zrounba, Philippe, additional, Roux, Pierre-Eric, additional, Poupart, Marc, additional, Vogin, Guillaume, additional, Foray, Nicolas, additional, and Pereira, Sandrine, additional

Published
2021
Full Text
View/download PDF

46. Impact of proton therapy on antitumor immune response

Author

Mirjolet, Céline, primary, Nicol, Anaïs, additional, Limange, Emeric, additional, Mura, Carole, additional, Richard, Corentin, additional, Morgand, Véronique, additional, Rousseau, Marc, additional, Boidot, Romain, additional, Ghiringhelli, François, additional, Noel, Georges, additional, and Burckel, Hélène, additional

Published
2021
Full Text
View/download PDF

49. Additional file 2: of Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

Author

Grapin, Mathieu, Richard, Corentin, Limagne, Emeric, Boidot, Romain, Morgand, Véronique, Bertaut, Aurélie, Derangere, Valentin, Pierre-Antoine Laurent, Thibaudin, Marion, Fumet, Jean, Crehange, Gilles, Ghiringhelli, François, and Mirjolet, Céline

Abstract

Figure S1. Gating strategy for lymphoid cells identification and quantification in tumor tissue. Figure S2. Gating strategy for myeloid and tumor cells identification, quantification and phenotype (PD-L1 expression) in tumor tissue. Figure S3. Gating strategy for lymphoid cells functionality quantification in tumor tissue. Figure S4. Efficacy evaluation of immunotherapy (anti-PD-L1 and/or anti-TIGIT) and RT (3x8Gy) in B16-F10 model. Growth of irradiated tumors in mice treated with IgG + 0Gy (black), IgG + 3x8Gy (red), anti-TIGIT + anti-PD-L1 (blue) and with anti-TIGIT + anti-PD-L1 + 3x8Gy (purple). Mean ± SEM. X axes express the number of days since the beginning of RT. Y axes express the tumor volume (mm3). Experimental groups contained at 5 mice per group. Non-parametric Mann-Whitney test was used. Figure S5. Immunomonitoring of Treg and CD8+ T cells and their KI67 and PD-1 status after radiotherapy. Ten days after the injection of CT26 colon murine cancer, mice were assigned in 4 groups: control (at day 7), 1 × 16.4Gy (red), 3x8Gy (blue), 18x2Gy (purple) (a). Seven, 14 and 30 days after the beginning of RT, flow cytometry monitoring (FCM) was performed on dissociated tumors. CD8+ T cells (a) and Treg T cells (b) were analyzed according to their status for KI67 and PD-1 labelling. All data are shown with box and whiskers with min to max values obtained from 8 independent samples per point (duplicate, n = 8 per condition). In the second part of a) and b), representative cytometry analysis was highlighted for each condition at day 7 and day 14 after treatment. *p

Published
2019
Full Text
View/download PDF

50. Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups

Author

Azelie Caroline, Gauthier Mélanie, Mirjolet Céline, Cormier Luc, Martin Etienne, Peignaux-Casasnovas Karine, Truc Gilles, Chamois Jérôme, Maingon Philippe, and Créhange Gilles

Subjects
Prostate cancer, IGRT, IMRT, Postoperative radiotherapy, Exclusive radiotherapy, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background To investigate whether patients treated for a localized prostate cancer (PCa) require a radical prostatectomy followed by postoperative radiotherapy or exclusive radiotherapy, in the modern era of image guided IMRT. Methods 178 patients with PCa were referred for daily exclusive image guided IMRT (IG-IMRT) using an on-line 3D ultra-sound based system and 69 patients were referred for postoperative IMRT without image guidance after radical prostatectomy (RP + IMRT). Patients were matched in a 1:1 ratio according to their baseline risk group before any treatment. Late toxicity was scored using the CTV v3.0 scale. Biochemical failure was defined as a postoperative PSA ≤ 0.1 ng/mL followed by 1 consecutive rising PSA for the postoperative group of patients and by the Phoenix definition (nadir + 2 ng/mL) for the group of patients treated with exclusive radiotherapy. Results A total of 98 patients were matched (49:49). From the start of any treatment, the median follow-up was 56.6 months (CI 95% = [49.6-61.2], range [18.2-115.1]). No patient had late gastrointestinal grade ≥ 2 toxicity in the IG-IMRT group vs. 4% in the RP + IMRT group. Forty two percent of the patients in both groups had late grade ≥ 2 genitourinary toxicity. The 5-year FFF rates in the IG-IMRT group and in the RP + IMRT groups were 93.1% [80.0-97.8] and 76.5% [58.3-87.5], respectively (p = 0.031). Conclusions Patients with a localized PCa treated with IG-IMRT had better oncological outcome than patients treated with RP + IMRT. Further improvements in postoperative IMRT using image guidance and dose escalation are urgently needed.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results